PLACENTAL-TRANSFER OF SULINDAC AND ITS ACTIVE SULFIDE METABOLITE IN HUMANS

被引:26
作者
KRAMER, WB [1 ]
SAADE, G [1 ]
OU, CN [1 ]
ROGNERUD, C [1 ]
DORMAN, K [1 ]
MAYES, M [1 ]
MOISE, KJ [1 ]
机构
[1] BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030
关键词
SULINDAC; SULFIDE METABOLITE; PLACENTAL TRANSFER; PROSTAGLANDIN SYNTHETASE INHIBITOR;
D O I
10.1016/0002-9378(95)90016-0
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: Our aim was to investigate whether the human placenta is permeable to sulindac or its active sulfide metabolite. STUDY DESIGN: Nine pregnant patients (median gestational age [range]: 31.8 [24.3 to 36.4] weeks) were given a 200 mg oral dose of sulindac 5.5 (4.4 to 6.7) hours before 18 intravascular transfusions for rhesus or Kell alloimmunization. At each procedure maternal and fetal serum levels of sulindac and the active sulfide metabolite were measured by high-performance liquid chromatography. RESULTS: The maternal sulfide level was significantly higher than the fetal sulfide levels, but no significant difference was noted between maternal and fetal sulindac levels. The sulfide fetal/maternal ratio was significantly lower than the sulindac fetal/maternal ratio. The sulfide/sulindac ratio was significantly higher in maternal serum versus fetal serum. The sulfide/sulindac ratio correlated with time from drug ingestion to sampling on the maternal side only. In patients studied on more than one occasion no consistent relationship between fetal sulindac, fetal sulfide, or fetal sulfide/sulindac ratio, and gestational age could be demonstrated. CONCLUSION: The placenta is permeable to sulindac but less so to its active sulfide metabolite. The reduction of sulindac to its active sulfide metabolite is decreased in the human fetus.
引用
收藏
页码:886 / 890
页数:5
相关论文
共 17 条
[1]  
AMON E, 1992, MED FETUS MOTHER, P1398
[2]  
CARLAN SJ, 1992, OBSTET GYNECOL, V79, P223
[3]   BIOMOLECULAR PROCESSES IN THE INITIATION OF PARTURITION - DECIDUAL ACTIVATION [J].
CASEY, ML ;
MACDONALD, PC .
CLINICAL OBSTETRICS AND GYNECOLOGY, 1988, 31 (03) :533-552
[4]  
CIABATTONI G, 1980, EUR J RHEUMATOL INFL, V3, P210
[5]  
DUGGAN DE, 1977, CLIN PHARMACOL THER, V21, P326
[6]  
HUCKER HB, 1973, DRUG METAB DISPOS, V1, P721
[7]   APPEARANCE OF PROSTAGLANDIN F2ALPHA IN HUMAN BLOOD DURING LABOUR [J].
KARIM, SMMM .
BRITISH MEDICAL JOURNAL, 1968, 4 (5631) :618-&
[8]   LONG-TERM INDOMETHACIN THERAPY DECREASES FETAL URINE OUTPUT AND RESULTS IN OLIGOHYDRAMNIOS [J].
KIRSHON, B ;
MOISE, KJ ;
MARI, G ;
WILLIS, R .
AMERICAN JOURNAL OF PERINATOLOGY, 1991, 8 (02) :86-88
[9]  
Kwan K C, 1977, Acta Rhumatol Belg, V1, P168
[10]   INDOMETHACIN IN THE TREATMENT OF PREMATURE LABOR - EFFECTS ON THE FETAL DUCTUS-ARTERIOSUS [J].
MOISE, KJ ;
HUHTA, JC ;
SHARIF, DS ;
OU, CN ;
KIRSHON, B ;
WASSERSTRUM, N ;
CANO, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (06) :327-331